{"name":"Boryung Biopharma Co., Ltd.","slug":"boryung-biopharma-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BR-TD-1001","genericName":"BR-TD-1001","slug":"br-td-1001","indication":"Alzheimer's disease","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"DTaP-IPV combination vaccine","genericName":"DTaP-IPV combination vaccine","slug":"dtap-ipv-combination-vaccine","indication":"Prevention of diphtheria, tetanus, pertussis, and poliomyelitis in infants and children","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Td-pur inj","genericName":"Td-pur inj","slug":"td-pur-inj","indication":"Cancer immunotherapy (specific indication not publicly confirmed)","status":"phase_3"}]}],"pipeline":[{"name":"BR-TD-1001","genericName":"BR-TD-1001","slug":"br-td-1001","phase":"phase_3","mechanism":"BR-TD-1001 is a dual-acting compound that modulates both TrkA and p75NTR signaling pathways involved in neuroinflammation and neurodegeneration.","indications":["Alzheimer's disease","Mild cognitive impairment"],"catalyst":""},{"name":"DTaP-IPV combination vaccine","genericName":"DTaP-IPV combination vaccine","slug":"dtap-ipv-combination-vaccine","phase":"phase_3","mechanism":"This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and poliovirus by delivering inactivated toxins and viral antigens.","indications":["Prevention of diphtheria, tetanus, pertussis, and poliomyelitis in infants and children"],"catalyst":""},{"name":"Td-pur inj","genericName":"Td-pur inj","slug":"td-pur-inj","phase":"phase_3","mechanism":"Td-pur is an immunotherapeutic injection designed to stimulate anti-tumor immune responses through a purified tumor-associated antigen or dendritic cell-based approach.","indications":["Cancer immunotherapy (specific indication not publicly confirmed)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBMS3hjWTNIcE5DVkxYeE54OF95b0xYNHZjUFE2VkNKS21oSXktRDh2S1dEQXhOTUM0NkNRZ0xhOHFTRU9CUkVzcms5SUJRejRRV1dIWHdRNURzWVh4VHlUMm9lRUNQQ3N6d0NxLUhR0gFyQVVfeXFMUEp5WTRSU0pkYjZyNXozVHUtd1NlSVJMd3QtSXFGQld2cXF6eEI0SEhaU1l3enROTUgwcTlXVXdTeFF0LWFWOFUydGxpMzM0WDdJcS1xd2RkZWM5dlJxUmdTdk8tYWFXVWNCTGdpNXNfOGRB?oc=5","date":"2025-03-31","type":"pipeline","source":"koreabiomed.com","summary":"Boryung CEO charts bold future with space healthcare vision, reinforces pharma core - koreabiomed.com","headline":"Boryung CEO charts bold future with space healthcare vision, reinforces pharma core","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE52RTFFdzRIRW8xTmJ6YVNkNGpGb1gtOXVpeU42MFZlLTQ2VXBsaWlodFY4dVpHQVZtTjdZV2JnMk5QdUx1YWY5b21ZOUVZUWtJejhBRVRtX0ZyT0Zja2FDdEZPYWJMNnUwZlRBWklR0gFyQVVfeXFMT1otNWpndGpXbHdEcGlGWU1Hd2ktaFhTcTB6MHlCWHVKNkRkUTdwTFJ5MGd4SG00YUhDQmMwTmN1d2xqMnItSTFZSEx2UjRrRF9mTXBSWXF4TnVINWpaQjd0Z3M1bmJjbjduU3RRS2d6eFBB?oc=5","date":"2025-03-04","type":"pipeline","source":"koreabiomed.com","summary":"Boryung shifts to sole CEO system, strengthening growth and space expansion - koreabiomed.com","headline":"Boryung shifts to sole CEO system, strengthening growth and space expansion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxQLUdGNExlVk1Yb25WMVhZWUlQUzgteV93WGRaSHU4WWZzMDFUYURLQXV5dFdHM3JTcERzSVQ5eUlLOFRSTXFsak8xdFJ4RmpHblB6YXJWY0tXMnhrQWluUk5OTkRqWTZvWHB0UkUyMndISW9XSS1tNDhnTDVnZmVxZm1lWUVLM3VVb2Y0dzJ2ZDExNWlhNk84RERxRkJSY2RubzhfSHZPZ3JpQ1NhSWV3ODltTlc3TF9ZWlV4LXFNWV9EdFlOT1RQNnFGeVotT3l3LWhmd2Z1Y19DcmtfQzJqdDlSaFlsZWJhWmlPMVluVkIzTmRPcTQxcDZ1UkhicGVfQUFqZ3QtZHVfTEQ1RXB4UmFkVkRmeXduUU1XQzM2YU5Jb002cnNpb01B?oc=5","date":"2024-11-28","type":"trial","source":"PR Newswire","summary":"Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therape","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE94YVdybTFFY3NVZWhtZDBwX0t3aHlOUEVQOFVPM0lZTXV0Sk9pUjFWb3NTWUdTb2xnRDBYN2YzcGgzTlhYV0lLRU5NX2JEb3k1VnkyakxybjV3VlNYWndPZVhfNmhrT2tDWHctSVFTVndUU1RvTnctWHgyQQ?oc=5","date":"2024-06-27","type":"deal","source":"KED Global","summary":"Eugene PE, KDB PE to acquire Boryung Biopharma for $231 million - KED Global","headline":"Eugene PE, KDB PE to acquire Boryung Biopharma for $231 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBXZmdjazRZRVhEcHQtM3JudjRqQzhNNDU2VlpfNXhKQkl1MkVmOWVTdC1Ja1BPV3BFZ0pWZkRvdHJKbC1JQXFIaXNfbm1KWDQ4TUxWUDUycHBMRDVDbUJtNkpJZmpRaG0tTnJ3Q2Vn?oc=5","date":"2023-12-20","type":"pipeline","source":"KED Global","summary":"Boryung, HK inno.N to co-market Kanarb, K-CAB - KED Global","headline":"Boryung, HK inno.N to co-market Kanarb, K-CAB","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1GaHFBU0JsSXZZTUM1eElsWV9JbzNEMVVfaGZKMTZMc0c4WkRTeTBQODdZOUNaSHZjMXFFOE1Cazl6ZzdQblViNnZKQ3UxVnhsOU5JNzdZY3FyeW9pN2FzLXZGZDhYR2xEdXZtOXBB?oc=5","date":"2023-09-06","type":"pipeline","source":"KED Global","summary":"S.Korea's Boryung gets gov’t OK for diabetes drug Trubuddy - KED Global","headline":"S.Korea's Boryung gets gov’t OK for diabetes drug Trubuddy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1ZZVV4emZWUlNsOW1RVThRRS0tamJLTDhhbm1MOHZuZEc4OGNReVZXLS1admhJY1lnM0RHX1BBNWtnY0pUcC15OFhpNWxraEpjMEhFRVFLcnZYX3JYMl9YczI0Zjk2YWg1VnhlZDhn0gFyQVVfeXFMUHVPN0oxSGJXd0tJczRSZDVDR0hQMWRWelktUlNUWmFnU1hjNDY0c2pmQnJQWFE5RlNYVU1MS2dLS2lsMTdnbU5VZ2g5aUdESXBVemNfWGtlZ2dpaENRNE5hdHhmY1VybDZXbkgwS3FYSVd3?oc=5","date":"2023-08-07","type":"pipeline","source":"koreabiomed.com","summary":"Boryung’s cancer drug gets 'developmental orphan drug' designation - koreabiomed.com","headline":"Boryung’s cancer drug gets 'developmental orphan drug' designation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBmbjNJbXdTSXFYUlZnLWlVM1hIN2tUOFgtU2tPMnM5d0lyazQtQ3A1RTAwMy1Vd2pNUWw4RFIxemk3c1h1dldoTV9BNmNwejRmSkFHTlV6WDVIWjF5ektkRXpKOTBZa05aMy05Snln?oc=5","date":"2023-06-14","type":"pipeline","source":"KED Global","summary":"S.Korea's SK Bioscience to resume domestic flu vaccine output - KED Global","headline":"S.Korea's SK Bioscience to resume domestic flu vaccine output","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5DX1NwVUJCTWNtblNJTW9LaHhQWWhjZ0JqNzU3cFdRUnloN0FidW9lQ2wwbHFsLUJ6ZXdrMUxNN0hBdUVRZmozSHBuN29uZTRlTWpoeXdSQ3JWOU5hb1NZZDM0N3pMTWJqamIxLUFn0gFyQVVfeXFMTkQ0YktiMFUwbGVGb1F6YXhvQmxHWVhmN2k3akpFZkl5dXJQVUpjNjRHcnM2ZEd2QTVfSm4zcmF5X1BNMkFsVDJ0V3lJN2ZJQkpjUnc0OVRTQVZ3NlJPWGp1ajFqcmpHdGpSVGF0RFI0dm9n?oc=5","date":"2022-09-27","type":"regulatory","source":"koreabiomed.com","summary":"Boryung's licensed-in lung cancer drug wins approval in Korea - koreabiomed.com","headline":"Boryung's licensed-in lung cancer drug wins approval in Korea","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOV2xYUXBSbGxZVDhJWWpZSUlpS3VRam5qWnBnOElUZGE4dEd1LVZTb1l1aktBOVNvTkdjWlRiZXJaSG94SlNmWjFJaUpoT1Ywa1ozS0JxLTlNQThwLTY3NGlDRmFmTDdxaFE0Z3JqT1VzMzVVZmJ2Ykhaa2tTd1dqdm1kMWVTcG5uTXBZUUotY2FDb2Fzc0xnYnFQNnFCTW54UmhxbFc4X3F4S2lLeC0yZ1dnaTZzQkJ3eFIwNkF2VUg?oc=5","date":"2020-10-22","type":"pipeline","source":"The Guardian","summary":"Doctors in South Korea call for flu vaccinations to be paused after 25 deaths - The Guardian","headline":"Doctors in South Korea call for flu vaccinations to be paused after 25 deaths","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE8xeXFWMnNlS1NNb2M1b3BoYlhWUkFEM2hJR1lDRktfcC1BUWJtRy1KQ2NXd3JLN2hHVGZhOEQyaUEwWEM4VWZMTXZXY0IzQ3h1VEVaMF96NA?oc=5","date":"2020-08-12","type":"trial","source":"바이오스펙테이터","summary":"Autotelic Bio expands its management team to accelerate clinical trial for ATB-301 and ASO based platform technology development - 바이오스펙테이터","headline":"Autotelic Bio expands its management team to accelerate clinical trial for ATB-301 and ASO based platform technology dev","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}